Upload

Loading icon Loading...

This video is unavailable.

Interview with Dr Laurence Klotz on plans for new clinical trials in prostate cancer

Sign in to YouTube

Sign in with your Google Account (YouTube, Google+, Gmail, Orkut, Picasa, or Chrome) to like FUSFoundation's video.

Sign in to YouTube

Sign in with your Google Account (YouTube, Google+, Gmail, Orkut, Picasa, or Chrome) to dislike FUSFoundation's video.

Sign in to YouTube

Sign in with your Google Account (YouTube, Google+, Gmail, Orkut, Picasa, or Chrome) to add FUSFoundation's video to your playlist.

Uploaded on Feb 14, 2011

Laurence Klotz, M.D., a urologic oncologist at the University of Toronto's Sunnybrook Health Sciences Centre, says planning is underway for a second clinical trial using an investigational transurethral ultrasound device developed at Sunnybrook to ablate prostate cancer.
The new study will build on the results of a 2009-2010 clinical trial that assessed the device's ability to deliver ultrasound energy to a targeted area within the prostate. Klotz explains. "We found that the correlation is very tight. All the tissue that was destroyed was within about a millimeter of our target."
In the first study, eight patients were treated with the device and then had a radical prostatectomy.
Patients participating in the new study will have their cancer targeted by the device and then undergo a prostatectomy. Post-surgical assessment will determine if the device effectively destroyed their cancer.

Loading icon Loading...

Loading icon Loading...

Loading icon Loading...

The interactive transcript could not be loaded.

Loading icon Loading...

Loading icon Loading...

Ratings have been disabled for this video.
Rating is available when the video has been rented.
This feature is not available right now. Please try again later.

Loading icon Loading...

Loading...
Working...
to add this to Watch Later

Add to